Elevating your intimacy with sexual health wellness protocols
52%
the average amount of men that suffer from ED.
40%
roughly 10% of women suffer from Hypoactive Sexual Desire Disorder (HSDD) and studies indicate that up to 40% of women may experience it at some point in their lives
PT-141
A synthetic melanocortin receptor agonist that primarily targets melanocortin receptors (MC3R/MC4R) involved in central nervous system signaling, studied for its role in modulating sexual arousal pathways and neurobehavioral responses independent of vascular mechanisms. Premium Research Peptide.
$129.99
Dosage
Fast Free Shipping
Shipment Protection
10mg
Size
HPLC≥99%
Purity
Lyophilized Powder
Form
Peptide products offered through this platform are provided for informational and research purposes or are made available only pursuant to evaluation and authorization by a licensed healthcare provider, where applicable. These products are not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary. Use of any peptide product should be conducted under appropriate professional supervision. All content provided is for educational purposes only and should not be considered medical advice. Always consult with a qualified healthcare professional before beginning any new wellness or medical program.
PT-141
PT-141 is a heptapeptide derivative of Melanotan II, engineered to selectively activate melanocortin receptors (MC3R and MC4R). Research has investigated these receptors for their involvement in central arousal pathways, energy balance mechanisms, and vascular tone regulation.
The cyclic structure of PT-141 has been studied for enhanced stability and receptor selectivity characteristics compared to native α-MSH fragments, making it a useful tool in melanocortin receptor research.
Structure:
Formula:
CAS Number:
Molecular Weight:
Research Focus:
Cyclic heptapeptide (Melanotan II derivative)
C50H68N14O10
189691-06-3
1025.2 g/mol
Melanocortin receptors, CNS pathways
PT-141 is administered subcutaneously in research settings and is currently under investigation for CNS melanocortin pathways, vascular modulation mechanisms, and central arousal research in laboratory studies.
Sources: National Institute of Health (nih.gov), ResearchGate, Lippincott (Obstetrics & Gynecology)
Neuera™ is an independent platform and is not affiliated with, endorsed by, or sponsored by the National Institutes of Health (NIH) or any other government organization. Product names, logos, brands, and other trademarks featured or referred to within this website are the property of their respective trademark holders. These names and logos are used strictly for identification, educational, and source-referencing purposes.